FGF23 is a novel regulator of intracellular calcium and cardiac contractility in addition to cardiac hypertrophy

Chad D. Touchberry, Troy M. Green, Vladimir Tchikrizov, Jaimee E. Mannix, Tiffany F. Mao, Brandon W. Carney, Magdy Girgis, Robert J. Vincent, Lori A. Wetmore, Buddhadeb Dawn, Lynda F. Bonewald, Jason R. Stubbs, Michael J. Wacker

Research output: Contribution to journalArticle

96 Citations (Scopus)

Abstract

Fibroblast growth factor 23 (FGF23) is a hormone released primarily by osteocytes that regulates phosphate and vitamin D metabolism. Recent observational studies in humans suggest that circulating FGF23 is independently associated with cardiac hypertrophy and increased mortality, but it is unknown whether FGF23 can directly alter cardiac function. We found that FGF23 significantly increased cardiomyocyte cell size in vitro, the expression of gene markers of cardiac hypertrophy, and total protein content of cardiac muscle. In addition, FGFR1 and FGFR3 mRNA were the most abundantly expressed FGF receptors in cardiomyocytes, and the coreceptor α-klotho was expressed at very low levels. We tested an animal model of chronic kidney disease (Col4a3-/- mice) that has elevated serum FGF23. We found elevations in common hypertrophy gene markers in Col4a3-/- hearts compared with wild type but did not observe changes in wall thickness or cell size by week 10. However, the Col4a3-/- hearts did show reduced fractional shortening (-17%) and ejection fraction (-11%). Acute exposure of primary cardiomyocytes to FGF23 resulted in elevated intracellular Ca2+ ([Ca2+]i; F/Fo + 86%) which was blocked by verapamil pretreatment. FGF23 also increased ventricular muscle strip contractility (67%), which was inhibited by FGF receptor antagonism. We hypothesize that although FGF23 can acutely increase [Ca2+]i, chronically this may lead to decreases in contractile function or stimulate cardiac hypertrophy, as observed with other stress hormones. In conclusion, FGF23 is a novel bone/heart endocrine factor and may be an important mediator of cardiac Ca2+ regulation and contractile function during chronic kidney disease.

Original languageEnglish (US)
Pages (from-to)E863-E873
JournalAmerican Journal of Physiology - Endocrinology and Metabolism
Volume304
Issue number8
DOIs
StatePublished - Apr 15 2013
Externally publishedYes

Fingerprint

Cardiomegaly
Calcium
Cardiac Myocytes
Fibroblast Growth Factor Receptors
Chronic Renal Insufficiency
Cell Size
Hormones
fibroblast growth factor 23
Osteocytes
Verapamil
Vitamin D
Hypertrophy
Observational Studies
Myocardium
Animal Models
Phosphates
Gene Expression
Bone and Bones
Muscles
Messenger RNA

Keywords

  • Cardiac function
  • Chronic kidney disease
  • Col4a3
  • Fibroblast growth factor 23
  • Pathological cardiac hypertrophy
  • α-klotho

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Physiology
  • Physiology (medical)

Cite this

FGF23 is a novel regulator of intracellular calcium and cardiac contractility in addition to cardiac hypertrophy. / Touchberry, Chad D.; Green, Troy M.; Tchikrizov, Vladimir; Mannix, Jaimee E.; Mao, Tiffany F.; Carney, Brandon W.; Girgis, Magdy; Vincent, Robert J.; Wetmore, Lori A.; Dawn, Buddhadeb; Bonewald, Lynda F.; Stubbs, Jason R.; Wacker, Michael J.

In: American Journal of Physiology - Endocrinology and Metabolism, Vol. 304, No. 8, 15.04.2013, p. E863-E873.

Research output: Contribution to journalArticle

Touchberry, CD, Green, TM, Tchikrizov, V, Mannix, JE, Mao, TF, Carney, BW, Girgis, M, Vincent, RJ, Wetmore, LA, Dawn, B, Bonewald, LF, Stubbs, JR & Wacker, MJ 2013, 'FGF23 is a novel regulator of intracellular calcium and cardiac contractility in addition to cardiac hypertrophy', American Journal of Physiology - Endocrinology and Metabolism, vol. 304, no. 8, pp. E863-E873. https://doi.org/10.1152/ajpendo.00596.2012
Touchberry, Chad D. ; Green, Troy M. ; Tchikrizov, Vladimir ; Mannix, Jaimee E. ; Mao, Tiffany F. ; Carney, Brandon W. ; Girgis, Magdy ; Vincent, Robert J. ; Wetmore, Lori A. ; Dawn, Buddhadeb ; Bonewald, Lynda F. ; Stubbs, Jason R. ; Wacker, Michael J. / FGF23 is a novel regulator of intracellular calcium and cardiac contractility in addition to cardiac hypertrophy. In: American Journal of Physiology - Endocrinology and Metabolism. 2013 ; Vol. 304, No. 8. pp. E863-E873.
@article{3bf517183903424f80b2335887e57eb1,
title = "FGF23 is a novel regulator of intracellular calcium and cardiac contractility in addition to cardiac hypertrophy",
abstract = "Fibroblast growth factor 23 (FGF23) is a hormone released primarily by osteocytes that regulates phosphate and vitamin D metabolism. Recent observational studies in humans suggest that circulating FGF23 is independently associated with cardiac hypertrophy and increased mortality, but it is unknown whether FGF23 can directly alter cardiac function. We found that FGF23 significantly increased cardiomyocyte cell size in vitro, the expression of gene markers of cardiac hypertrophy, and total protein content of cardiac muscle. In addition, FGFR1 and FGFR3 mRNA were the most abundantly expressed FGF receptors in cardiomyocytes, and the coreceptor α-klotho was expressed at very low levels. We tested an animal model of chronic kidney disease (Col4a3-/- mice) that has elevated serum FGF23. We found elevations in common hypertrophy gene markers in Col4a3-/- hearts compared with wild type but did not observe changes in wall thickness or cell size by week 10. However, the Col4a3-/- hearts did show reduced fractional shortening (-17{\%}) and ejection fraction (-11{\%}). Acute exposure of primary cardiomyocytes to FGF23 resulted in elevated intracellular Ca2+ ([Ca2+]i; F/Fo + 86{\%}) which was blocked by verapamil pretreatment. FGF23 also increased ventricular muscle strip contractility (67{\%}), which was inhibited by FGF receptor antagonism. We hypothesize that although FGF23 can acutely increase [Ca2+]i, chronically this may lead to decreases in contractile function or stimulate cardiac hypertrophy, as observed with other stress hormones. In conclusion, FGF23 is a novel bone/heart endocrine factor and may be an important mediator of cardiac Ca2+ regulation and contractile function during chronic kidney disease.",
keywords = "Cardiac function, Chronic kidney disease, Col4a3, Fibroblast growth factor 23, Pathological cardiac hypertrophy, α-klotho",
author = "Touchberry, {Chad D.} and Green, {Troy M.} and Vladimir Tchikrizov and Mannix, {Jaimee E.} and Mao, {Tiffany F.} and Carney, {Brandon W.} and Magdy Girgis and Vincent, {Robert J.} and Wetmore, {Lori A.} and Buddhadeb Dawn and Bonewald, {Lynda F.} and Stubbs, {Jason R.} and Wacker, {Michael J.}",
year = "2013",
month = "4",
day = "15",
doi = "10.1152/ajpendo.00596.2012",
language = "English (US)",
volume = "304",
pages = "E863--E873",
journal = "American Journal of Physiology",
issn = "0193-1849",
publisher = "American Physiological Society",
number = "8",

}

TY - JOUR

T1 - FGF23 is a novel regulator of intracellular calcium and cardiac contractility in addition to cardiac hypertrophy

AU - Touchberry, Chad D.

AU - Green, Troy M.

AU - Tchikrizov, Vladimir

AU - Mannix, Jaimee E.

AU - Mao, Tiffany F.

AU - Carney, Brandon W.

AU - Girgis, Magdy

AU - Vincent, Robert J.

AU - Wetmore, Lori A.

AU - Dawn, Buddhadeb

AU - Bonewald, Lynda F.

AU - Stubbs, Jason R.

AU - Wacker, Michael J.

PY - 2013/4/15

Y1 - 2013/4/15

N2 - Fibroblast growth factor 23 (FGF23) is a hormone released primarily by osteocytes that regulates phosphate and vitamin D metabolism. Recent observational studies in humans suggest that circulating FGF23 is independently associated with cardiac hypertrophy and increased mortality, but it is unknown whether FGF23 can directly alter cardiac function. We found that FGF23 significantly increased cardiomyocyte cell size in vitro, the expression of gene markers of cardiac hypertrophy, and total protein content of cardiac muscle. In addition, FGFR1 and FGFR3 mRNA were the most abundantly expressed FGF receptors in cardiomyocytes, and the coreceptor α-klotho was expressed at very low levels. We tested an animal model of chronic kidney disease (Col4a3-/- mice) that has elevated serum FGF23. We found elevations in common hypertrophy gene markers in Col4a3-/- hearts compared with wild type but did not observe changes in wall thickness or cell size by week 10. However, the Col4a3-/- hearts did show reduced fractional shortening (-17%) and ejection fraction (-11%). Acute exposure of primary cardiomyocytes to FGF23 resulted in elevated intracellular Ca2+ ([Ca2+]i; F/Fo + 86%) which was blocked by verapamil pretreatment. FGF23 also increased ventricular muscle strip contractility (67%), which was inhibited by FGF receptor antagonism. We hypothesize that although FGF23 can acutely increase [Ca2+]i, chronically this may lead to decreases in contractile function or stimulate cardiac hypertrophy, as observed with other stress hormones. In conclusion, FGF23 is a novel bone/heart endocrine factor and may be an important mediator of cardiac Ca2+ regulation and contractile function during chronic kidney disease.

AB - Fibroblast growth factor 23 (FGF23) is a hormone released primarily by osteocytes that regulates phosphate and vitamin D metabolism. Recent observational studies in humans suggest that circulating FGF23 is independently associated with cardiac hypertrophy and increased mortality, but it is unknown whether FGF23 can directly alter cardiac function. We found that FGF23 significantly increased cardiomyocyte cell size in vitro, the expression of gene markers of cardiac hypertrophy, and total protein content of cardiac muscle. In addition, FGFR1 and FGFR3 mRNA were the most abundantly expressed FGF receptors in cardiomyocytes, and the coreceptor α-klotho was expressed at very low levels. We tested an animal model of chronic kidney disease (Col4a3-/- mice) that has elevated serum FGF23. We found elevations in common hypertrophy gene markers in Col4a3-/- hearts compared with wild type but did not observe changes in wall thickness or cell size by week 10. However, the Col4a3-/- hearts did show reduced fractional shortening (-17%) and ejection fraction (-11%). Acute exposure of primary cardiomyocytes to FGF23 resulted in elevated intracellular Ca2+ ([Ca2+]i; F/Fo + 86%) which was blocked by verapamil pretreatment. FGF23 also increased ventricular muscle strip contractility (67%), which was inhibited by FGF receptor antagonism. We hypothesize that although FGF23 can acutely increase [Ca2+]i, chronically this may lead to decreases in contractile function or stimulate cardiac hypertrophy, as observed with other stress hormones. In conclusion, FGF23 is a novel bone/heart endocrine factor and may be an important mediator of cardiac Ca2+ regulation and contractile function during chronic kidney disease.

KW - Cardiac function

KW - Chronic kidney disease

KW - Col4a3

KW - Fibroblast growth factor 23

KW - Pathological cardiac hypertrophy

KW - α-klotho

UR - http://www.scopus.com/inward/record.url?scp=84878487994&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878487994&partnerID=8YFLogxK

U2 - 10.1152/ajpendo.00596.2012

DO - 10.1152/ajpendo.00596.2012

M3 - Article

C2 - 23443925

AN - SCOPUS:84878487994

VL - 304

SP - E863-E873

JO - American Journal of Physiology

JF - American Journal of Physiology

SN - 0193-1849

IS - 8

ER -